Tyra Biosciences, Inc. (TYRA)
USD 14.52
(-4.6%)
USD 14.52
(-4.6%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Operating Cash Flow | -50.13 Million | -50.28 Million | -23.74 Million | -7.76 Million | -2.61 Million |
| Net Income | -69.13 Million | -55.32 Million | -26.29 Million | -9.33 Million | -4.06 Million |
| Depreciation & Amortization | 353 Thousand | 296 Thousand | 140 Thousand | 47 Thousand | 8000.00 |
| Deferred income taxes | -9.36 Million | - | - | 2000.00 | - |
| Stock-based compensation | 13.52 Million | 10.58 Million | 2.88 Million | 439 Thousand | - |
| Change in working capital | 6.36 Million | -5.84 Million | -481 Thousand | 1.07 Million | 505 Thousand |
| Other non-cash items | 8.12 Million | 3000.00 | 3000.00 | 15 Thousand | 934 Thousand |
| Investing Cash Flow | -144.6 Million | -559 Thousand | -645 Thousand | -312 Thousand | -20 Thousand |
| Investments in PPE | -770 Thousand | -559 Thousand | -661 Thousand | -312 Thousand | -20 Thousand |
| Acquisitions | - | - | 16 Thousand | - | - |
| Investment purchases | -143.83 Million | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - |
| Other Investing Activities | -143.83 Thousand | - | 16.00 | - | - |
| Financing Cash Flow | 1.53 Million | 632.00 | 311.34 Million | 23.43 Million | 157 Thousand |
| Debt repayment | - | - | -9000.00 | -17 Thousand | -8000.00 |
| Dividends payments | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - |
| Common Stock Issuance | 1.53 Million | 632 Thousand | 181.22 Million | 23.45 Million | 165 Thousand |
| Other Financing Activities | 1537.00 | 632.00 | 130.13 Million | 23.43 Thousand | 165 Thousand |
| Accounts receivables | - | - | - | - | - |
| Accounts payables | 9.36 Million | 2.35 Million | 1.49 Million | 1.01 Million | 461 Thousand |
| Inventory | - | - | - | - | - |
| Other working capital | -3 Million | -8.2 Million | -1.97 Million | 51 Thousand | 44 Thousand |
| Cash at beginning of period | 251.21 Million | 302.42 Million | 15.46 Million | 108 Thousand | 2.58 Million |
| Cash at end of period | 58 Million | 252.21 Million | 302.42 Million | 15.46 Million | 108 Thousand |
| Capital Expenditure | -770 Thousand | -559 Thousand | -661 Thousand | -312 Thousand | -20 Thousand |
| Effect of forex changes on cash | - | - | - | - | - |
| Net cash flow / Change in cash | -193.2 Million | -50.21 Million | 286.95 Million | 15.35 Million | -2.48 Million |
| Free Cash Flow | -50.9 Million | -50.84 Million | -24.4 Million | -8.07 Million | -2.63 Million |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -18.7 Million | -18.19 Million | -22.83 Million | -69.13 Million | -21.15 Million | -13.27 Million |
| Depreciation & Amortization | 126 Thousand | 122 Thousand | 102 Thousand | 353 Thousand | 82 Thousand | 86 Thousand |
| Deferred income taxes | - | - | -4.39 Million | -9.36 Million | - | - |
| Stock-based compensation | 4.41 Million | 4.11 Million | 4.18 Million | 13.52 Million | 4.37 Million | 2.52 Million |
| Change in working capital | 5.77 Million | -6.84 Million | 6.25 Million | 6.36 Million | -453 Thousand | 1.03 Million |
| Other non-cash items | 2.79 Million | 3.13 Million | 3.14 Million | 8.12 Million | 1000.00 | 3000.00 |
| Investing Cash Flow | -144.99 Million | 18.07 Million | -144.43 Million | -144.6 Million | -83 Thousand | -43 Thousand |
| Investments in PPE | -470 Thousand | -136 Thousand | -603 Thousand | -770 Thousand | -83 Thousand | -43 Thousand |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | -177.4 Million | -11.79 Million | -143.83 Million | -143.83 Million | - | - |
| Sales/Maturities of investments | 32.88 Million | 30 Million | - | - | - | - |
| Other Investing Activities | -144.52 Thousand | 18.2 Thousand | -143.83 Thousand | -143.83 Thousand | - | - |
| Financing Cash Flow | 373 Thousand | 200.31 Million | 324 Thousand | 1.53 Million | 467 Thousand | 370 Thousand |
| Debt repayment | - | - | - | - | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | -251 Thousand | -169 Thousand | - | - | - | - |
| Common Stock Issuance | 373 Thousand | 200.31 Million | 324 Thousand | 1.53 Million | 467 Thousand | 370 Thousand |
| Other Financing Activities | 373.00 | 200.31 Thousand | 324.00 | 1537.00 | 467.00 | 370.00 |
| Accounts receivables | - | - | - | - | - | - |
| Accounts payables | - | -6.9 Million | 11.39 Million | 9.36 Million | - | - |
| Inventory | - | - | - | - | - | - |
| Other working capital | 5.77 Million | -6.84 Million | 6.25 Million | -3 Million | -453 Thousand | 1.03 Million |
| Cash at beginning of period | 254.36 Million | 58 Million | 215.65 Million | 251.21 Million | 233.41 Million | 242.7 Million |
| Cash at end of period | 99.49 Million | 254.36 Million | 58 Million | 58 Million | 216.65 Million | 233.41 Million |
| Capital Expenditure | -470 Thousand | -136 Thousand | -603 Thousand | -770 Thousand | -83 Thousand | -43 Thousand |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | -154.87 Million | 196.36 Million | -157.64 Million | -193.2 Million | -16.76 Million | -9.28 Million |
| Free Cash Flow | -10.72 Million | -22.16 Million | -14.13 Million | -50.9 Million | -17.22 Million | -9.65 Million |
300628
SIGY
IVZ
PLFF
000428
600095